Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2024-09-01 DOI:10.21873/anticanres.17196

Takashi Kamigaki, Rishu Takimoto, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Shigenori Goto

{"title":"Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens.","authors":"Takashi Kamigaki, Rishu Takimoto, Sachiko Okada, Hiroshi Ibe, Eri Oguma, Shigenori Goto","doi":"10.21873/anticanres.17196","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer immunotherapy activates the host immune system against tumor cells and has the potential to lead to the development of innovative strategies for cancer treatment. Neoantigens are non-self-antigens produced by genetic mutations in tumor cells that induce a strong immune response against tumor cells without central immune tolerance. Along with advances in neoantigen analysis technology, the development of vaccines focusing on neoantigens is being accelerated. Whereas there are various platforms for neoantigen vaccines, combined immuno-therapies are being developed simultaneously with the clinical application of synthetic long peptides and mRNA and dendritic-cell (DC)-based vaccines. Personalized DC-based vaccines not only can load various antigens including neoantigens, but also have the potential to elicit a strong immune response in T cells as antigen-presenting cells. In this review, we describe the properties of neoantigens and the basic characteristics of DCs. We also discuss the clinical applications of neoantigen vaccines, focusing on personalized DC-based vaccines, as well as future research and development directions and challenges.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17196","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Cancer immunotherapy activates the host immune system against tumor cells and has the potential to lead to the development of innovative strategies for cancer treatment. Neoantigens are non-self-antigens produced by genetic mutations in tumor cells that induce a strong immune response against tumor cells without central immune tolerance. Along with advances in neoantigen analysis technology, the development of vaccines focusing on neoantigens is being accelerated. Whereas there are various platforms for neoantigen vaccines, combined immuno-therapies are being developed simultaneously with the clinical application of synthetic long peptides and mRNA and dendritic-cell (DC)-based vaccines. Personalized DC-based vaccines not only can load various antigens including neoantigens, but also have the potential to elicit a strong immune response in T cells as antigen-presenting cells. In this review, we describe the properties of neoantigens and the basic characteristics of DCs. We also discuss the clinical applications of neoantigen vaccines, focusing on personalized DC-based vaccines, as well as future research and development directions and challenges.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

针对癌症新抗原的个性化树突状细胞疫苗。

癌症免疫疗法可激活宿主免疫系统对抗肿瘤细胞，并有可能开发出创新的癌症治疗策略。新抗原是肿瘤细胞基因突变产生的非自身抗原，可诱导针对肿瘤细胞的强烈免疫反应，而不会产生中心免疫耐受。随着新抗原分析技术的进步，以新抗原为重点的疫苗开发也在加速。虽然新抗原疫苗有多种平台，但随着合成长肽和 mRNA 以及基于树突状细胞 (DC) 的疫苗的临床应用，联合免疫疗法也在同步发展。基于树突状细胞的个性化疫苗不仅能装载包括新抗原在内的各种抗原，而且有可能在作为抗原递呈细胞的 T 细胞中引起强烈的免疫反应。在这篇综述中，我们描述了新抗原的特性和 DC 的基本特征。我们还讨论了新抗原疫苗的临床应用，重点是基于 DC 的个性化疫苗，以及未来的研发方向和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.